Tocilizumab
Stage III Renal Pelvis Cancer AJCC v8
M.D. Anderson Cancer Centermonoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 89/ 100
Competitive context
10 Active assets in the Stage III Renal Pelvis Cancer AJCC v8 cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide Alliance for Clinical Trials in Oncology | Phase 3 | B |
Nivolumab M.D. Anderson Cancer Center | Phase 2 | B |
Pembrolizumab Alliance for Clinical Trials in Oncology | Phase 3 | B |
Epirubicin Alliance for Clinical Trials in Oncology | Phase 3 | B |
Ipilimumab M.D. Anderson Cancer Center | Phase 2 | B |
View all 11 →
Same molecule, other indications
Tocilizumab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →